Table 1.
Baseline characteristics of the unmatched and matched cohort
| Characteristics | Unmatched Cohort | Matched Cohort | ||||
|---|---|---|---|---|---|---|
| No Treatment | Apixaban | Standardized Difference | No Treatment | Apixaban | Standardized Difference | |
| No. of patients | 10,976 | 521 | 1561 | 521 | ||
| Demographics | ||||||
| Age | 67±13 | 68±11 | −0.03 | 68±13 | 68±11 | 0.04 |
| Men | 5920 (54%) | 281 (54%) | 0.00 | 824 (53%) | 281 (54%) | 0.02 |
| Black race | 3378 (31%) | 116 (22%) | −0.19 | 333 (21%) | 116 (22%) | 0.02 |
| Hemodialysis | 9831 (90%) | 453 (87%) | −0.08 | 1374 (88%) | 453 (87%) | −0.03 |
| Dialysis vintage, mo | 26 (10–57) | 19 (6–33) | 0.33 | 19 (6–38) | 19 (6–33) | 0.01 |
| Comorbidities | ||||||
| Hypertension | 10,916 (100%) | 520 (100%) | 0.05 | 1557 (100%) | 520 (100%) | 0.02 |
| Diabetes | 8778 (80%) | 419 (80%) | 0.01 | 1251 (80%) | 419 (80%) | 0.01 |
| Coronary disease | 8302 (76%) | 387 (74%) | −0.03 | 1150 (74%) | 387 (74%) | 0.01 |
| Heart failure | 8243 (75%) | 397 (76%) | 0.03 | 1187 (76%) | 397 (76%) | 0.00 |
| Myocardial infarction | 2953 (27%) | 110 (21%) | −0.14 | 349 (22%) | 110 (21%) | −0.03 |
| Stroke history | 4375 (40%) | 178 (34%) | −0.12 | 564 (36%) | 178 (34%) | −0.04 |
| PVD | 6571 (60%) | 285 (55%) | −0.11 | 854 (55%) | 285 (55%) | 0.00 |
| Dyslipidemia | 9333 (85%) | 472 (91%) | 0.17 | 1420 (91%) | 472 (91%) | −0.01 |
| Malignancy | 3163 (29%) | 149 (29%) | 0.00 | 457 (29%) | 149 (29%) | −0.02 |
| Alcohol-related disease | 1603 (15%) | 59 (11%) | −0.10 | 175 (11%) | 59 (11%) | 0.00 |
| Liver disease | 3550 (32%) | 134 (26%) | −0.15 | 371 (24%) | 134 (26%) | 0.04 |
| COPD | 4755 (43%) | 207 (40%) | −0.07 | 606 (39%) | 207 (40%) | 0.02 |
| Bleeding history | 6346 (58%) | 254 (49%) | −0.18 | 752 (48%) | 254 (49%) | 0.01 |
| Medication | ||||||
| ACEI | 3301 (30%) | 134 (26%) | −0.10 | 384 (25%) | 134 (26%) | 0.03 |
| ARB | 2030 (19%) | 97 (19%) | 0.00 | 293 (19%) | 97 (19%) | −0.01 |
| Antiplatelet agent | 2688 (25%) | 117 (23%) | −0.05 | 356 (23%) | 117 (23%) | −0.01 |
| β-Blocker | 7564 (69%) | 379 (73%) | 0.08 | 1126 (72%) | 379 (73%) | 0.01 |
| Statin | 5806 (53%) | 313 (60%) | 0.15 | 942 (60%) | 313 (60%) | 0.00 |
Results are presented as mean ± SD, median (interquartile range), or number (percentage). PVD, peripheral vascular disease; COPD, chronic obstructive pulmonary disease; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.